Powered by 100% renewable energy, Cytiva’s new 80,000 square feet manufacturing facility will open its doors in Grens (canton of Vaud) at the end of May 2022.
The site will manufacture single use kits for the Sepax and Sefia cell processing systems, as well as consumables for Xuri cell expansion systems. It will also serve as a Center of Excellence for Cytiva’s Cell and Gene Therapy business, and will be a base for European customer training programs.
The new facility will quadruple Cytiva’s capacity for manufacturing Sefia, Sepax, and Xuri consumable products with two new ISO class 7 cleanrooms, ensuring that increased future demand can be met. The design of the facility adopts GMP principles from raw materials entering the building, through the manufacturing process, to the shipment of finished products.
Built to Swiss Minergie standards, the manufacturing facility’s design is aligned with Cytiva’s mission to integrate sustainability into its operations. Building to this standard provides high-grade, air-tight building envelopes and the continuous renewal of air in the building using an energy-efficient ventilation system.
The building is powered by 100% renewable electricity and has roof mounted solar panels. It also has five distinct HVAC systems that optimize environmental conditions in each functional area.
A testament to the Health Valley’s innovation ecosystem
Catarina Flyborg, Vice President, Cell and Gene Therapy of Cytiva, says : “Cell and gene therapies have the potential to change the global healthcare landscape. Our new facility in Grens will enable us to meet global demand for our products, while working with our customers to meet their immediate training and development needs. This facility brings us another step closer to our vision where access to life-changing therapies transforms human health.”
Located in the heart of the Health Valley, the new site will be home to 250 employees. Cytiva’s existing site in Eysins will continue operations through 2023, while full production transfers to the facility in Grens.
Philippe Leuba, Minister of Economic Affairs, Innovation and Sport of the canton of Vaud, stated : “Cytiva is one of the world’s leading life sciences companies. Its decision to expand operations in Switzerland is a testament to our innovation ecosystem that has played a significant role in developing some of the most advanced therapeutics.”
